Neuromyelitis optica

References cited
Article section 15 of 16.  Previous  Next

By Tiffani Stroup DO and Adil Javed MD PhD

Adoni T, Lino A, Marchiori P, Kok F, Callegaro D. Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica. Arq Neuropsiquiatr 2008;66(2-B):295-7.

Ahasan HA, Rafiqueuddin AK, Chowdhury MA, et al. Neuromyelitis optica (Devic's disease) following chicken pox. Trop Doct 1994;24(2):75-6.

Albutt TC. On the ophthalmoscopic signs of spinal disease. Lancet 1870;1:76-8.

Awad A, Stuve O. Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol 2011;9(3):417-28.

Banwell B, Tenembaum S, Lennon V, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008;70:344-52.

Bergamaschi R. Immune agents for the treatment of Devic’s neuromyelitis optica. Neurol Sci 2007;28:238-40.

Bergamaschi R, Tonietti S, Franciotta D, et al. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 2004;10(1):2-4.

Blanche P, Diaz E, Gombert B, et al. Devic's neuromyelitis optica and HIV-1 infection. J Neurol Neurosurg Psychiatry 2000;68(6):795-6.

Capobianco M, Malucchi S, Di Sapio A, et al. Variable responses to rituximab in neuromyelitis optica (Devic’s disease). Neurol Sci 2007;28:209-11.

Cassinotto C, Joux J, Chausson N, Smadja D, Cabre P. Failure of rituximab in relapsing neuromyeltic optica : case report with two-year prospective follow-up. [French] Rev Neurol (Paris) 2008;164:394-7.

Ch'ien LT, Medeiros MO, Belluomini JJ, et al. Neuromyelitis optica (Devic's syndrome) in two sisters. Clin Electroencephalogr 1982;13(1):36-9.

Chusid MJ, Williamson SJ, Murphy JV, Ramey LS. Neuromyelitis optica (Devic disease) following varicella infection. J Pediatr 1979;95(5 Pt 1):737-8.

Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270-2.

Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5(3):611-5.

Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 2004;83(5):280-91.

de Seze J, Blanc F, Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol 2008;65(7):920-3.

Devic ME. Myélite subaiguë compliquée de névrite optique. Bull Méd (Paris) 1894;8:1033-4.

Fazekas F, Offenbacher H, Schmidt R, Strasser-Fuchs S. MRI of neuromyelitis optica: evidence for a distinct entity. J Neurol Neurosurg Psychiatry 1994;57(9):1140-2.

Feng X, Reder NP, Yanamandala M, et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci 2012;313(1-2):48-53.

Ferraro A. Primary demyelinating processes of the central nervous system: an attempt at unification and classification. Arch Neurol Psychiatry 1937;37:1100-60.

Filippi M, Rocca MA, Moiola L, et al. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology 1999;53(8):1705-10.

Freitas E, Guimaraes J. Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatol Int 2015;35(2):243-53.

Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol 2004;251(1):47-52.

Goulden C. Optic neuritis and myelitis. Opthalmic Rev 1914;34:193-209.

Haase CG. Devics neuromyelitis optica. Disease or variants of multiple sclerosis? Nervenarzt 2001;72(10):750-4.

Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88.

Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66(4):460-71.

Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013;84(8):922-30.

Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65(11):1443-8.

Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306(1-2):82-90.

Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6(7):383-92.

Jarius S, Wildemann B. Aquaporin-4 Antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 2013;23(6):661-83.

Javed A, Arnason B, Reder AT. Breakthrough relapses after rituximab in NMO patients: incidence and other treatment options. 24th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), ACTRIMS, and LACTRIMS. Montréal, Canada. Mult Scler 2008a;14(Suppl 1):P69, S49.

Javed A, Balabanov R, Arnason B, et al. Minor salivary gland inflammation in Devic’s disease and longitudinally extensive myelitis. Mult Scler 2008b;14:809-14.

Jeffery AR, Buncic JR. Pediatric Devic's neuromyelitis optica. J Pediatr Ophthalmol Strabismus 1996;33(5):223-9.

Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol 1998;44(4):629-34.

Keefe RJ. Neuromyelitis optica with increased intracranial pressure. AMA Arch Ophthalmol 1957;57(1):110-1.

Khan MI. Neuromyelitis optica (relapsing type). J Pak Med Assoc 1976;26(3):61-3.

Kim W, Kim SH, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 2012;78(16):1264-7.

Kira J. Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis. Pathophysiology 2011;18(1):69-79.

Kister I, Gulati S, Boz C, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006;63(6):851-6.

Kuroiwa Y. Neuromyelitis optica (Devic's disease, Devic syndrome). In: Koetsier JC, editor. Handbook of clinical neurology. New York: Elsevier Science; 1985:397-408.

Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-7.

Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106-12.

Levy M, Wildemann B, Jarius S, et al. Immunopathogenesis of neuromyelitis optica. Adv Immunol 2014;121:213-42.

Loschner AL, Snyder JE. Pelvic pain as an unusual first presentation of a demyelinating disease. J Gen Intern Med 2008;23(11):1917-20.

Lotze T, Northrop J, Hutton G. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008;122;e1039-47.

Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125(Pt 7):1450-61.

Lumsden CE. Fundamental problems in the pathology of multiple sclerosis and allied demyelinating diseases. Br Med 1957;1:1035-43.

Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51(4):1219-20.

Mandler RN, Davis LE, Jeffery DR, et al. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34(2):162-8.

Marrie RA, Gryba C. The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care 2013;15(3):113-18.

Martin JR. Spinal cord and optic nerve demyelination in experimental herpes simplex virus type 2 infection. J Neuropathol Exp Neurol 1982;41(3):253-66.

McAlpine D. Familial neuromyelitis optica: its occurrence in identical twins. Brain 1938;61:430-8.

Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012;69(9):1176-80.

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014;71(3):324-30.

Merelli E, Bedin R, Sola P, et al. Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults and children. J Neurol 1997;244(7):450-4.

Merle H, Olindo S, Donnio A. Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest Ophthalmol Vis Sci 2008;49(10):4412-7.

Mok C, To C, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatology 2008;35:172-4.

Nozaki I, Hamaguchi T, Komai K, et al. Fulminant Devic's disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry 2006;77(9):1094-5.

O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996;60(4):382-7.

Pittock, SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008;65(5):629-32.

Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non-organ-specific immunity. Arch Neurol 2008;65(1):78-83.

Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006a;63(3):390-6.

Pittock SJ, Weinshenker BG, Wingerchuk DM, et al. Autoimmune neurological accompaniments of neuromyelitis optica (NMO). Chicago: American Neurological Association, 2006c:S38, M-24.

Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011;76(14):1229-37.

Pueyo V, Martin J, Fernandez J. Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. Mult Scler 2008;14:609-14.

Putnam TJ, Foster FM. Neuromyelitis optica: its relation to multiple sclerosis. Trans Am Neurol Assoc 1942;68:20-5.

Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009;73(4):302-8.

Ren Z, Wang Y, Duan T, et al. Cross-immunoreactivity between bacterial aquaporin-z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol 2012;189(9):4602-11.

Sahraian MA, Radue EW, Minagar A. Neuromyelitis optica: clinical manifestations and neuroimaging features. Neurol Clin 2013;31(1):139-52.

Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev 2009;9(2):132-5.

Sato DK, Callegaro D, Lana-Peixoto MA, et al. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis. Arq Neuropsiquiatr 2014;72(6):445-50.

Sato D, Fujihara K. Atypical presentations of neuromyelitis optica. Arq Neuropsiquiatr 2011;69(5):824-8.

Silber MH, Willcox PA, Bowen RM, Unger A. Neuromyelitis optica (Devic's syndrome) and pulmonary tuberculosis. Neurology 1990;40(6):934-8.

Stansbury FC. Neuromyelitis optica (Devic disease): presentation of five cases with pathological study and review of the literature. Arch Ophthalmol 1949;42:293-335.

Tackley G, Kuker W, Palace J. Magnetic resonance imaging in neuromyelitis optica. Mult Scler 2014. [Epub ahead of print]

Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 2008;79:1075-8.

Tobin WO, Weinshenker BG, Lucchinetti CF. Longitudinally extensive transverse myelitis. Curr Opin Neurol 2014;27(3):279-89.

Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261(1):1-16. 

Tsivgoulis G, Kontokostas S, Boviatsis E, Bonakis A, Stefanis L, Voumvourakis K. Teaching neuroimages: neuromyelitis optica misdiagnosed as spinal cord tumor. Neurology 2014;82(4):e33. 

Uzawa A, Mori M, Kuwabara S. Neuromyelitis optica: concept, immunology and treatment. J Clin Neurosci 2014;21(1):12-21. 

Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize clostridium ABC transporter. Ann Neurol 2012;72(1):53-64. 

Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004;77(4):542-8.

Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007;252(1):57-61.

Weinshenker BG. Neuromyelitis optica: what it is and what it might be. Lancet 2003;361(9361):889-90.

Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59(3):566-9.

Weinstock-Guttman B, Ramanathan M, Lincoff N. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957-63.

Whitham RH, Brey RL. Neuromyelitis optica: two new cases and review of the literature. J Clin Neuroophthalmol 1985;5(4):263-9.

Wilcox R, Burrow J, Slee M. Neuromyelitis optica (Devic’s disease) in a patient with syphilis. Mult Scler 2008;14:268-71.

Williamson PM. Neuromyelitis optica following infectious mononucleosis. Proc Aust Assoc Neurol 1975;12:153-5.

Wingerchuk D, Banwell B, Bennett J, et al. Revised diagnostic criteria for neuromyelitis optica spectrum disorders. 66th AAN Annual Meeting. Philadelphia, PA, 2014:S63.001.

Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53(5):1107-14.

Wingerchuk DM, Lennon VA, Sittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.

Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60(5):848-53.

Yamakawa K, Kuroda H, Fujihara K, et al. Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan. Neurology 2000;55(2):318-20.

**References especially recommended by the author or editor for general reading

In This Article

Historical note and nomenclature
Clinical manifestations
Clinical vignette
Pathogenesis and pathophysiology
Differential diagnosis
Diagnostic workup
Prognosis and complications
References cited